ACE OncoCast

Updates on Oncogene-Driven NSCLC from Vienna: Targeting KRAS G12C mutation

ACE Oncology Season 4 Episode 2

Use Left/Right to seek, Home/End to jump to start or end. Hold shift to jump forward or backward.

0:00 | 11:15

In this episode, our experts discuss current and new strategies for targeting KRAS G12C mutation. Hear about emerging strategies to enhance activity of current treatment options in this molecular subtype.